# A Phase IIa Clinical Study of Purinostat Mesylate for Injection in Patients With Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma

> **NCT06485219** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Chengdu Zenitar Biomedical Technology Co., Ltd** · enrollment: 50 (estimated)

## Conditions studied

- Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
- Cutaneous T-cell Lymphoma (CTCL)

## Interventions

- **DRUG:** 11.2 mg/m2 Purinostat Mesylate
- **DRUG:** 15 mg/m2 Purinostat Mesylate

## Key facts

- **NCT ID:** NCT06485219
- **Lead sponsor:** Chengdu Zenitar Biomedical Technology Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-04-14
- **Primary completion:** 2026-06-30
- **Final completion:** 2026-12-31
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2026-02-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06485219

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06485219, "A Phase IIa Clinical Study of Purinostat Mesylate for Injection in Patients With Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06485219. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*